Interferon Alpha-2: Pre-Clinical and Clinical Evaluation

indgår i serie Developments in Oncology


Studiebog
Interferon Alpha-2: Pre-Clinical and Clinical Evaluation
Du sparer Spar kr. 40,00 med Shopping-fordele
  • Leveringstid 6-10 hverdage (Sendes fra fjernlager)
  • Forventet levering 03-11-2021
For at købe bogen til fordelspris skal du have et medlemskab med Shopping-fordele.
Du kan prøve medlemskabet gratis i 30 dage. Medlemskabet fornyes automatisk og kan altid opsiges.
Format:
Bog, paperback
Udgivelsesdato:
01-10-2011
Sprog:
Engelsk
Udgave:
Softcover reprint of the original 1st ed. 1985.
  • Beskrivelse
  • Yderligere info
  • Anmeldelser

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

Vis mereVis mindre

Udgivelsesdato:
01-10-2011
ISBN13:
9781461296188
Vægt:
207 g
Dybde:
7 mm
Bredde:
155 mm
Højde:
235 mm
Nummer i serien:
27
Format:
Paperback
Forfattere

    Vis mereVis mindre

    Vis mereVis mindre

    Fandt du ikke hvad du søgte?

    Hvis denne bog ikke er noget for dig, kan du benytte kategorierne nedenfor til at finde andre titler. Klik på en kategori for at se lignende bøger.

    Velkommen til Saxo – din danske boghandel!

    Hos os kan du handle som gæst, Saxo-bruger eller Premium-medlem – du bestemmer helt selv. Skulle du få brug for hjælp, sidder vores kundeservice-team klar ved både telefonerne og tasterne.

    Om fordelspriser hos Saxo

    For at købe bøger til fordelspris, skal du være medlem af Premium, Premium Shopping eller Premium Studie. De første 30 dage er gratis for nye medlemmer. Medlemskabet fornyes automatisk og kan altid opsiges. Læs mere om fordelene ved vores forskellige medlemskaber her.

    Machine Name: SAXO082